ArticleJournal of natural products2026
Total Synthesis and Biological Evaluation of Leptosphaerone B and Derivatives of Microketide A.
Article in Journal of natural products, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microketide A and B are fungal polyketides reported to display potent activity against Gram-negative pathogens, yet the lack of synthetic access has prevented detailed investigation of their mode of action and structure-activity relationship (SAR). Here, we report the first total synthesis of two close analogs of microketide A, dihydro-MikA and 11-deoxy-MikA, as well as of racemic leptosphaerone B, another member of this cyclohexenone-based natural product family. Our route features a modular assembly of highly functionalized fragments and enables divergent access to analogs through selective dihydroxylation and late-stage fragment fusion. Despite extensive exploration of multiple C-C bond-forming strategies, unfavorable sterics and competing eliminations prevented successful connection of the fragments required for microketide A. The synthesized compounds leptosphaerone B, dihydro-MikA, and 11-deoxy-MikA were evaluated for antibacterial activity and human cytotoxicity but showed no effects up to 200 μM. Competitive residue-specific chemoproteomics and in vitro nucleophile-trapping experiments further revealed no covalent protein engagement, indicating that these scaffolds are intrinsically weak electrophiles. Our findings suggest that microketide A possesses a restrictive SAR, in which even subtle modifications abolish biological function. The synthetic strategy described herein provides a robust platform for in-depth structure activity relationship studies assessing the biological potential of this natural product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.